ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VRP Verona Pharma Plc

55.00
0.00 (0.00%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 55.00 45.00 65.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Verona Pharma Share Discussion Threads

Showing 13051 to 13072 of 13325 messages
Chat Pages: 533  532  531  530  529  528  527  526  525  524  523  522  Older
DateSubjectAuthorDiscuss
17/7/2020
20:02
Grotesquely underpriced share offering. The chairman needs to be removed for permitting this massive transfer of value from existing smaller shareholders to new shareholders who have never done anything for the company.
tradertrev
17/7/2020
15:48
Happy days I got in at 68p earlier.
rk23
17/7/2020
14:16
market cap post fundraising is near £500m

"... it has raised approximately $200 million (GBP159
million*) in an oversubscribed private placement and subscription with
new and existing institutional and accredited investors (the
"Financing"). The Financing comprises a private placement of 39,090,009
of the Company's American Depositary Shares ("ADSs"), each representing
eight ordinary shares of the Company ("Ordinary Shares"), at a price of
$4.50 per ADS, and 43,111,112 of the Company's Ordinary Shares at the
equivalent price per Ordinary Share, being GBP0.45 or $0.5625 (together
the "Securities"). "

(39,090,009 * 8) + 43,111,112 + 106,481,006 (current shares in issue)

= 462,312,190 total ordinary shares, after fundraising

delta0091
17/7/2020
13:59
There's a systemic bias against this class of compound which goes back a long way, I think this has put the big companies off...
bonzo
17/7/2020
13:58
£10 plus would be very very nice, £3 by Christmas more realistic but if as you say the trials go well and they get approval, anything and everything is possibly. Tightly held! They raised £200 million yet market cap is £100m at app £1.00. Long way to go
murphy2000
17/7/2020
13:34
Lots of resistance around 3 £, after that it hit? Its all time high of 10.56 £ was on 1st sept 09, will it get there again? Most certainly on positive results and if Ensifentrine gets regulatory approval, who knows where a tightly held stock could go.
goggin
17/7/2020
13:28
Good call ;-)
lukic
17/7/2020
12:48
This looks good for 95-100 today.
rk23
17/7/2020
09:16
Results from Phase 1/11 has been good/v good. Surprised if one big pharma has not considered taking up the baton from here.
ewads
17/7/2020
09:06
Unlikely to be early news from a phase 3 trial unless they use an adaptive design which gives an early indication of efficacy, or get an outstanding response which effectively unblinded the study.
bonzo
17/7/2020
08:12
Great news!!!
joeblogg2
17/7/2020
08:09
200 million - this sorts out Hugh uncertainty
goggin
17/7/2020
08:04
This injection is a massive vote of confidence for the credibility for the expected success of the company
ewads
17/7/2020
07:48
Woh, this removes uncertainty short term, any positive news and this will go crazy. It's positive news, they needed the cash big time. Could easily hit £7 plus if Ensifentrine hits the sweet spot
goggin
17/7/2020
07:18
Another substantial ammount raised at 0.45Not a great price.Still gonna be years away and another 200 million needed later down the lineGonna be dead by the time this company has anything real to show.Jobs for the boys, good salaries for all of them so no incentive to get a move on
pjm1162
17/7/2020
07:13
Inevitable dilution fir existing holders and not much price action until the Phase 3 outcome is known, I suspect.
bonzo
12/6/2020
11:58
...its hard to express what a dissappointing little scam of a share this is? Its always jam tomorrow then its diluted or retraced! Ive seen this over the 10 years I've been involved!
haff1
12/6/2020
11:22
Shared normally perks up close to a fund raise to get a better price. Only a possibility, but could happen here.
wageslave
12/6/2020
08:58
shakin, in my opinion the pending fund raise is a huge overhang which everyone knows about and will be tightly held by anyone who takes part, being the last fund raise before phase 3 trial results are known. The market can then focus on the commercial opportunity which is vast, so the chances of buying shares in the market below any offer price would appear to be slim.
tradertrev
12/6/2020
08:09
dilution on the way I reckon. Phase 3 starting end of third quarter and need to find over 90 million. The next global funding will be at a ridiculously low price but if given the chance to take part I will give it a big miss. Just wait for new shares to enter market and wait for inevitable drop of share price below offer and pick some up then
shakin not stirred
10/6/2020
18:51
https://copdnewstoday.com/2020/03/26/copd-patients-vulnerable-to-severe-covid-19-infections-study-finds/
goggin
30/5/2020
09:34
Could be ahead of webcast on Monday at 12.30pm to present the Phase 3 trial programme and the huge commercial case for enisfentrine. Should be positive IMO.
tradertrev
Chat Pages: 533  532  531  530  529  528  527  526  525  524  523  522  Older

Your Recent History

Delayed Upgrade Clock